If unqualified, Complete remission is considered to be Haematological complete remission
|
|
- Cory Shaw
- 5 years ago
- Views:
Transcription
1 Scroll right to see the database codes for Disease status and Response Diagnosis it refers to Disease status or response to treatment AML ALL CML CLL MDS or MD/MPN or acute leukaemia secondary to previous treatment of another disease Chronic phase Accelerated phase Blast crisis Progressive relapsing (malignant) None of the features of accelerated phase or blast crisis blasts 10-19% of WBCs in peripheral blood and/or nucleated bone marrow cells; peripheral blood basophils >=20%; persistent thrombocytopenia (<100 x 10 9 )/L unrelated to therapy; persistent thrombocytosis (>1000 x 10 9 /L) unresponsive to standard therapy; increasing spleen size and increasing WBC count unresponsive to standard therapy; cytogenetic evidence of clonal evolution blasts >=20% of peripheral blood white cells or nucleated bone marrow cells; extramedullary blast proliferation; large foci or clusters of blasts in the bone marrow biopsy Primary progressive Secondary progressive Relapsing/remitting Primary induction failure / Primary refractory Despite treatment patient has never achieved a complete remission Treatment with intent to achieve remission was given, but no Complete remission was achieved Stable disease (no change, no response) Stringent Complete remission (scr) Patients who have not achieved a CR or a PR, and who have not exhibited progression, will be considered to have no change Complete remission or response (CR) Haematological CR Cytogenetic CR Molecular CR CR confirmed For at least 4 weeks: < 5% blasts in the bone marrow No blasts with Auer rods (applies to AML only) Normal maturation of all cellular components in the bone marrow No extramedullary disease (e.g., CNS, soft tissue disease) Transfusion independent For at least 4 weeks: < 5% blasts in the bone marrow No blasts with Auer rods (applies to AML WBC<10X10 9 /L; only) Hemoglobin>11.0gm/dL; Normal maturation of all cellular platelet count<500x10 9 /L; components in the bone marrow normal differential (<1%precursor cells); no palpable splenomegaly; No extramedullary disease (e.g., CNS, no extramedullary disease; soft tissue disease) Transfusion independent Disappearance of cytogenetic anomalies Haematological remission if previously detected 0% positive (t(9;22) metaphases Disappearance of molecular anomalies if previously detected If unqualified, Complete remission is considered to be Haematological complete remission Haematological remission Cytogenetic remission (if cytogenetics done) Cells with the BCR/ABL fusion protein are not detectable in the peripheral blood and /or the bone marrow, by an assay with a sensitivity to allow detection of one t(9;22) positive cell in 10 5 to 10 6 RT-PCR cells. The result should be confirmed by two consecutive tests done at least 4 weeks apart. absence of clonal lymphocytes in the peripheral blood absence of significant lymphadenopathy (e.g. lymph nodes greater than 1,5 cm in diameter) absence of hepatomegaly or splenomegaly absence of constitutional symptoms Response must persist for a minimum duration of four weeks: Bone marrow with 5 percent myeloblasts with normal maturation of all cell lines. Dysplastic changes may be seen, but should be considered within the normal range of dysplastic changes. Peripheral blood demonstrates hemoglobin 11 g/dl, platelets 100 x 109/L, neutrophils 1 x 109/L, and no circulating blasts. CR unconfirmed
2 Disease status or response to treatment AML ALL CML CLL MDS or MD/MPN or acute leukaemia secondary to previous treatment of another disease First partial remission (PR1) Very good PR (VGPR) Partial remission or response Note: The specification (>1, never CR, Solid tum only) only applies to disease status in Solid Tumours For any other diagnosis, the disease status of PR can have been preceded by a relapsed CR Minimal respponse / Poor partial remission or response At leat one of the following: A decrease in the number of blood lymphocytes by below 50% or more from the value prior to therapy; A decrease in lymph node size by below 50% or more in the sum products of up to 6 lymph nodes, or in one lymph node diameter if only a single lymph node was present prior to therapy, without increase in any lymph node, and no new enlarged lymph node; A decrease in the size of the liver and/or spleen by 50% or more as defined by CT scan, palpation, or ultrasound. The blood count should show one of the following results if abnormal prior to therapy:. Polymorphonuclear leukocytes at 1.500/μL or more or 50% improvement over baseline without G-CSF support;. platelet counts greater than /μL or 50% improvement Response / improvement (no CR) Relapse > 5% blasts in the bone marrow after a period of Complete remission. If unqualified, Relapse is considered to be Haematological relapse At least one Complete remission was achieved with a previous treatment but the patient has relapsed since then Haematological Relapse > 5% blasts in the bone marrow after a period of Complete remission. Cytological and/or histological evidence of the disease in the marrow-blood and/or in extramedullary sites (CNS, testis, skin, etc.) in a patient considered to have been in Haematological complete remission Cytogenetic Relapse Reappearance of chromosome anomalies detected earlier in the history of the disease. Cytogenetic relapse can only be determined if Cytogenetic remission has been previously demonstrated. Presence of one or more t(9:22) positive metaphases with standard cytogenetics or hypermetaphase FISH and/or >2% cells with the BCR/ABL fusion gene by interphase FISH, in a patient lacking any evidence of the disease at haematological/clinical level.
3 Disease status or response to treatment AML ALL CML CLL MDS or MD/MPN or acute leukaemia secondary to previous treatment of another disease Molecular Relapse Reappearance of molecular anomalies detected earlier in the history of the disease. Molecular relapse can only be determined if Molecular remission has been previously demonstrated. Presence of one or more t(9:22) positive metaphases with standard cytogenetics or hypermetaphase FISH and/or >2% cells with the BCR/ABL fusion gene by interphase FISH, in a patient lacking any evidence of the disease at haematological/clinical level. untreated relapse sensitive (responding) relapse resistant relapse Progression [progression] resistant to chemotherapy [progression] sensitive to chemotherapy Untreated relapse (from a previous CR) or progression from a previous (PR) Progression of lymphadenopathy, defined as the occurrence of at least one of the following events...appearance of any new lesion such as enlarged lymph nodes (> 1.5 cm), splenomegaly, hepatomegaly or other organ infiltrates....an increase by 50% or more in greatest determined diameter of any previous site. More blasts in bone marrow than before treatment or...an increase of 50% or more in the sum of the product of leukaemic transformation diameters of multiple nodes. An increase in the liver or spleen size by 50% or more or the de novo appearance of hepatomegaly or splenomegaly. An increase in the number of blood lymphocytes by 50% or more with at least 5,000 B-cells per μl. Transformation to a more aggressive histology (e.g. Richter's syndrome). Patient received another treatment following progression but no remission of any type was achieved Patient received another treatment after progression and achieved some kind of remission Chemorefractory relapse or progression, including primary refractory disease Never in CR Not in CR Untreated/Upfront Patient has never been treated for this disease Patient has never been treated for this disease use only if more precise evaluation is use only if more precise evaluation is Treatment is supportive or there has not been any treatment at all (blood transfusions are not considered as treatment in this context) Adjuvant Not evaluable unknown if pat. died within 100 days after trans if data cannot be obtained
4 Scroll right to see the database codes for Disease status and Response Disease status or response to treatment Myelofibrosis (MPN) Lymphoma Plasma cell disorders; mainly Multiple myeloma Solid Tumors Chronic phase Accelerated phase Blast crisis Progressive relapsing (malignant) Primary progressive Secondary progressive Relapsing/remitting Primary induction failure / Primary refractory Doest not present any of the features of any type of remission after treatment The patient has not achieved any of the types of response described below until now with any type of therapy Stable disease (no change, no response) Stringent Complete remission (scr) Less than 50% reduction in the disease burden Does not meet the criteria for Complete remission, Very good partial remission, Partial remission or Progressive disease Complete remission as defined below normal free light chain ratio absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence Less than 50% reduction in the disease Complete remission or response (CR) Resolution of disease related symptoms and signs including palpable hepatosplenomegaly. Hb >11gr/dl, Platelet >100 x109/l and neutrophils >1 Complete absence of disease, no signs or x 109/L. symptoms of the original disease normal bone marrow histology, and fibrosis grade no higher than 1 The patient has achieved complete Absence of detectable monoclonal immunoglobulin in serum or monoclonal light absence of disease prior to HSCT chains in the urine by immunofixation. Detectable monoclonal immunoglobulin, even if and the HSCT is not part of any impossible to quantify, is not a Complete remission. adjuvant therapy <5% of plasma cells in bone marrow aspirate Disappearance of any soft tissue plasmacytomas. No increase in size or number of lytic lesions if assessed (radiographic studies are not mandatory) Haematological CR Cytogenetic CR Molecular CR CR confirmed no abnormalities detected in any scan a negative PET scan if there is previous history of a positive PET scan, even in the presence of abnormalities in the CT scan No abnormalities detected in scan CR unconfirmed Scan abnormalities of unknown significance in the absence of a negative PET scan Persistent scan abnormalities of unknown significance
5 Disease status or response to treatment Myelofibrosis (MPN) Lymphoma Plasma cell disorders; mainly Multiple myeloma Solid Tumors First partial remission (PR1) Patient achieved a reduction in disease of 50% or more for the first time ever, but did not achieve Complete remission Very good PR (VGPR) Serum and urine M-protein detectable by immunofixation but not on electrophoresis >90% reduction in serum M-protein plus urine M-protein level <0.1 g/ per 24h Plus no increase in size or number of lytic lesions if assessed (radiographic studies are not mandatory) Disease burden is reduced by at least 90% Partial remission or response Note: The specification (>1, never CR, Solid tum only) only applies to disease status in Solid Tumours For any other diagnosis, the disease status of PR can have been preceded by a relapsed CR Minimal respponse / Poor partial remission or response Reduction in the disease of 50% or more Second or subsequent time a >50% reduction in serum M-protein plus reduction in 24h urinary M-protein by >90% reduction in the disease of 50% or or to <0.2g/ per 24h more is achieved in patients who In the absence of measurable serum and urine M-protein, the following criteria have never achieved a Complete applies: remission... A decrease in the difference between involved and uninvolved free light chain (FLC) of more than 50% If the FLC assay cannot be measured, the following criteria applies:.- >50% reduction in plasma cells provided baseline bone marrow plasma cell percentage was >30% A reduction of more than 50% in the size of soft tissue plasmacytomas if present at pre-treatment. No increase in size or number of lytic lesions if assessed (radiographic studies are not mandatory) Response / improvement (no CR) Relapse At least one of the following in the absence of progression: Haemoglobin increase of 2 g/dl or transfusion independence Spleen reduction of 50% 100% increase in platelet count and an absolute platelet count of at least x 10 9 /L 100% increase in ANC and an ANC of at least 0.5 x Loss of Complete remission At least one of the following for patients whose last disease status was Complete remission: - Reappearance of measurable monoclonal immunoglobulin in serum or urine by immunofixation or electrophoresis - Appearance of more than 5% plasma cells in the bone marrow - Increase of old/appearance of new osteolytic bone lesions on x-ray - Appearance of soft tissue plasmacytoma Reappearance of disease in patients whose last disease status was Complete remission Haematological Relapse Cytogenetic Relapse
6 Disease status or response to treatment Myelofibrosis (MPN) Lymphoma Plasma cell disorders; mainly Multiple myeloma Solid Tumors Molecular Relapse Progression untreated relapse sensitive (responding) relapse resistant relapse At least one of the following progressive splenomegaly leukemic transformation an increase of peripheral blood blast percentage of at least 20% - Increase of 25% or more in measurable monoclonal immunoglobulin in serum or urine (absolute increase must be >0.5g/dL) - Increase of 25% or more in urinary light chains (absolute increase must be >0.2g/ per 24h)...In the absence of measurable serum and urine M-protein, the following criteria applies:.. - An increase of 25% or more in the difference between involved and uninvolved free light chain (absolute increase must be >0.01g/dL) - An increase of 25% or more in bone marrow plasma cells (absolute % must be >10%) - Increase of old/appearance of new osteolytic bone lesions on x-ray - Appearance of soft tissue plasmacytoma - Development of hypercalcemia (corrected serum calcium >11.5 mg/dl or 2.65 mmol/l) that can be attributed solely to the plasma cell disorder Patient has not been treated for this relapse Patient achieves a reduction of >50% in the disease burden after treatment for this relapse Patient has not achieved a reduction of more than 50% in the disease burden after treatment for this relapse [progression] resistant to chemotherapy [progression] sensitive to chemotherapy Untreated relapse (from a previous CR) or progression from a previous (PR) Chemorefractory relapse or progression, including primary refractory disease Never in CR Not in CR Untreated/Upfront Adjuvant not possible not possible Treatment is supportive or there has not been any treatment at all (blood transfusions are not considered as treatment in this context) Worsening of the disease status in patients in PR or re-appearance of the Lymphoma in patients in CR, such as: Occurrence of new sites of the disease Re-occurence of disease or systemic symptoms (B symptoms) Patient remains untreated after the relapse or progression Does not present any of the features of any type of remission after treatment Patient has never been treated for this disease Patient has never been treated for this disease Patient has never been treated for this disease and the high dose therapy is part of the overall treatment strategy Patient has no residual disease and the HSCT is part of the consolidation treatment; metastatic patients can never be considered as adjuvant. Not evaluable unknown splant
7 Scroll right to see the database codes for Disease status and Response Disease status or response to treatment Chronic phase Accelerated phase Data base codes Severe Aplastic anaemia (SAA) non Severe Aplastic anaemia (nsaa) Multiple sclerosis Disease status Response 1 2 Blast crisis 3 Progressive relapsing (malignant) Primary progressive Secondary progressive Relapsing/remitting Primary induction failure / Primary refractory Continuous disease progression with clear acute disease exacerbation episodes Continuous disease progression without distinct acute disease exacerbation episodes Acute disease exacerbations periods where there is disease progression after the acute disease exacerbation Acute disease exacerbation periods that resolve completely without worsening of neurologic functions Stable disease (no change, no response) Stringent Complete remission (scr) Still meeting criteria of severe aplastic anaemia and transfusion dependence Not meeting criteria of partial or complete response Complete remission or response (CR) haemoglobin normal for age neutrophils >= 1.5 x 10 9 /L platelets >= 150 x 10 9 /L (21) (22) (23) Haematological CR Cytogenetic CR Molecular CR CR confirmed CR unconfirmed
8 Disease status or response to treatment Severe Aplastic anaemia (SAA) non Severe Aplastic anaemia (nsaa) Multiple sclerosis Disease status Response First partial remission (PR1) 40 Very good PR (VGPR) (36) (37) (38) Partial remission or response Note: The specification (>1, never CR, Solid tum only) only applies to disease status in Solid Tumours For any other diagnosis, the disease status of PR can have been preceded by a relapsed CR All of the following transfusion independent no longer meeting criteria for severe aplastic anaemia (see MED-AB Manual) transfusion independence (if previously required) doubling or normalization of at least one cell line increase above baseline* by. 3 g/dl hemoglobin and. 0.5x10 9 /L neutrophils and. 20x10 9 /L platelets (31) (32) (33) Minimal respponse / Poor partial remission or response Response / improvement (no CR) All of the following transfusion independent levels of hemoglobin, neutrophils and platelets still meeting criteria for severe aplastic anaemia (see MED-AB Manual ) Relapse Haematological Relapse Cytogenetic Relapse
9 Disease status or response to treatment Severe Aplastic anaemia (SAA) non Severe Aplastic anaemia (nsaa) Multiple sclerosis Disease status Response Molecular Relapse untreated relapse sensitive (responding) relapse resistant relapse Progression [progression] resistant to chemotherapy [progression] sensitive to chemotherapy Untreated relapse (from a previous CR) or progression from a previous (PR) 51 Chemorefractory relapse or progression, including primary refractory disease Never in CR Not in CR Untreated/Upfront Adjuvant 75 Not evaluable unknown
If unqualified, Complete remission is considered to be Haematological complete remission
Scroll right to see the database codes for Disease status and Response Diagnosis it refers to Disease status or response to treatment AML ALL CML CLL MDS or MD/MPN or acute leukaemia secondary to previous
More informationTracking Disease Status for Multiple Myeloma
Tracking Disease Status for Multiple Myeloma This appendix is intended to provide additional resources when determining: Best response to line of therapy pre-transplant; Disease Status at the Last Evaluation
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL RESPONSE ASSESSMENT MYELOMA CHAPTER 11C REVISED: SEPTEMBER 2016
MYELOMA Quantitative Markers-Myeloma Assessment Quantitative markers are biochemicals that are recorded in tests on body fluids such as serum and urine. Applicable Disease Sites The myeloma disease site
More informationInstructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)
Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the CLL Post-HSCT Data Form. E-mail
More informationMYE FORMS REVEALED RESPONSE CODES OBJECTIVES. Stringent Complete Response (scr) Complete Response (CR) I have no conflicts of interest to disclose
I have no conflicts of interest to disclose MYE FORMS REVEALED Janet Brunner, PA-C CIBMTR MKE New10_1.ppt OBJECTIVES 1) Be able to describe the criteria required for each myeloma response code 2) Be able
More informationMyelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data
Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017
LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer
More informationCriteria for Disease Assessment Joan Bladé
Criteria for Disease Assessment Joan Bladé Unidad de Amiloidosis y Mieloma Servicio de Hematología Hospital Clínic de Barcelona COMy Meeting, París, May 4th, 2018 Response Evaluation EBMT, 1998 - CR and
More informationAppendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand
Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs
More informationInstructions for Plasma Cell Disorders (PCD) Post-HCT Data (Form 2116 Revision 3)
(Form 2116 Revision 3) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Plasma Cell Disorders (PCD) Post-HCT Data Form. E-mail comments regarding the
More informationWhat is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias
Hematology and Hematologic Malignancies Cancer of the formed elements of the blood What is a hematological malignancy? A hematologic malignancy is a malignancy (or cancer) of any of the formed elements
More informationJeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ
Jeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ What is acute leukemia? Cancer of the white blood cells Acute leukemia- Acute myelogenous leukemia Acute myeloid leukemia Myelofibrosis- Blast phase
More informationMyeloproliferative Disorders - D Savage - 9 Jan 2002
Disease Usual phenotype acute leukemia precursor chronic leukemia low grade lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2
More informationWBCs Disorders 1. Dr. Nabila Hamdi MD, PhD
WBCs Disorders 1 Dr. Nabila Hamdi MD, PhD ILOs Compare and contrast ALL, AML, CLL, CML in terms of age distribution, cytogenetics, morphology, immunophenotyping, laboratory diagnosis clinical features
More informationPlasma Cell Disorders (PCD) Pre-HCT Data
Plasma Cell Disorders (PCD) Pre-HCT Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: CIBMTR Recipient ID: Date of HCT for which this form is being completed: HCT type: (check
More informationr). SUPPLEMENTARY/SECOND OPPORTUNITY EXAMINATION PAPER nnmlbih UNIVERSITY Sophia Blaauw INSTRUCTIONS FACULTY OF HEALTH AND APPLIED SCIENCES
r). nnmlbih UNIVERSITY OF SCIEFICE nnd TECHNOLOGY FACULTY OF HEALTH AND APPLIED SCIENCES DEPARTMENT OF HEALTH SCIENCES QUALIFICATION: BACHELOR OF MEDICAL LABORATORY SCIENCES QUALIFICATION CODE: 08BMLS
More informationMyeloid neoplasms. Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories:
Myeloid neoplasms Note: Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories: 1. AML : Acute myeloid leukemia(stem cell with myeloid
More informationChronic Idiopathic Myelofibrosis (CIMF)
Chronic Idiopathic Myelofibrosis (CIMF) CIMF Synonyms Agnogenic myeloid metaplasia Myelosclerosis with myeloid metaplasia Chronic granulocytic-megakaryocytic myelosis CIMF Megakaryocytic proliferation
More informationMED B Form CLL. Johannes Schetelig. London 09/April/
www.ebmt.org MED B Form CLL Johannes Schetelig London 09/April/2013 Content Update on CLL (15 ) Experiment with mini MED B CLL Assessment of pre-treatment in CLL Cytogenetics in CLL What is the IGVH-Gene
More informationJuvenile Myelomonocytic Leukemia Pre-HCT Data
Instructions for Juvenile Myelomonocytic Leukemia Pre-HCT Data (Form 2015) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the JMML Pre-HCT Form. E-mail
More informationA 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable.
1 Case 1 A 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable. CBC and bone marrow aspiration and biopsy were done. Chromosome study showed she had t(9;22)
More informationHeme 9 Myeloid neoplasms
Heme 9 Myeloid neoplasms The minimum number of blasts to diagnose acute myeloid leukemia is 5% 10% 20% 50% 80% AML with the best prognosis is AML with recurrent cytogenetic abnormality AML with myelodysplasia
More informationCase Workshop of Society for Hematopathology and European Association for Haematopathology
Case 24 2007 Workshop of Society for Hematopathology and European Association for Haematopathology Aliyah Rahemtullah 1, Martin K Selig 1, Paola Dal Cin 2 and Robert P Hasserjian 1 Departments of Pathology,
More information2016: Plasma Cell Disorders Pre-HCT Data
2016: Plasma Cell Disorders Pre-HCT Data Registry Use Only Sequence Number: Date Received: Key Fields CIBMTR Center Number: Date of HCT for which this form is being completed: / / YYYY MM DD HCT type (check
More informationGroup of malignant disorders of the hematopoietic tissues characteristically associated with increased numbers of white cells in the bone marrow and
Group of malignant disorders of the hematopoietic tissues characteristically associated with increased numbers of white cells in the bone marrow and / or peripheral blood Classified based on cell type
More informationLeukemias. Prof. Mutti Ullah Khan Head of Department Medical Unit-II Holy Family Hospital Rawalpindi Medical College
Leukemias Prof. Mutti Ullah Khan Head of Department Medical Unit-II Holy Family Hospital Rawalpindi Medical College Introduction Leukaemias are malignant disorders of the haematopoietic stem cell compartment,
More informationLeukemia and Myelodysplastic Syndromes
Leukemia and Myelodysplastic Syndromes Lenise Taylor, RN, MN, AOCNS Heme Malignancies/BMT CNS Seattle Cancer Care Alliance/UWMC Lymphoid 1 Myeloid 2 Presenting Signs and Symptoms Diagnostic Evaluation
More informationFlow Cytometry. Leukemia and Myelodysplastic Syndromes. Bone Marrow Aspirate and Biopsy
Diagnostic Evaluation of Blood Disorders Leukemia and Myelodysplastic Syndromes Lenise Taylor, MN, RN, AOCNS, BMTCN BMT/Immunotherapy CNS Seattle Cancer Care Alliance/UWMC ltaylor@seattlecca.org History
More informationHematology 101. Rachid Baz, M.D. 5/16/2014
Hematology 101 Rachid Baz, M.D. 5/16/2014 Florida 101 Epidemiology Estimated prevalence 8,000 individuals in U.S (compare with 80,000 MM patients) Annual age adjusted incidence 3-8/million-year 1 More
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy
More informationMYELOPROLIFARATIVE NEOPLASMS. Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin).
MYELOPROLIFARATIVE NEOPLASMS Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin). These are a group of chronic conditions characterised by clonal proliferation of marrow precursor cells. PRV, essential thrombocyathaemia,
More informationa resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation
a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation This resource has been developed to help guide you regarding the appropriate timing and conditions for a referral
More informationHAEMATOLOGICAL MALIGNANCY
HAEMATOLOGICAL MALIGNANCY Reference Compulsory reading Haematology at Glance 2 nd ed. Atul Mehta & Victor Hoffbrand Chapters: 20 to 31 Pages: 46 to 69 Pathogenesis of Haematological Malignancy Figure (a)
More informationCase #1. 65 yo man with no prior history presented with leukocytosis and circulating blasts: Bone marrow biopsy was performed
Case #1 65 yo man with no prior history presented with leukocytosis and circulating blasts: WBC 187.4K/uL ; Hgb 10.0gm/dL; Platelet 68K/uL Neutrophil % 25.0% Lymphocyte % 38.0% Monocyte % 12.0% Metamyelocyte
More informationPathology. #11 Acute Leukemias. Farah Banyhany. Dr. Sohaib Al- Khatib 23/2/16
35 Pathology #11 Acute Leukemias Farah Banyhany Dr. Sohaib Al- Khatib 23/2/16 1 Salam First of all, this tafreegh is NOT as long as you may think. If you just focus while studying this, everything will
More informationFlow Cytometry. Bone Marrow Aspirate and Biopsy. Leukemia and Myelodysplastic Syndromes
Diagnostic Evaluation of Blood Disorders Leukemia and Myelodysplastic Syndromes Elise Frans, MN, RN, CWON Oncology CNS University of Washington Medical Center delterzo@uw.edu 1 History & Physical Labs:
More informationRory McCulloch. Specialty Trainee Haematology Royal Devon & Exeter Hospital
Rory McCulloch Specialty Trainee Haematology Royal Devon & Exeter Hospital Anaemia 1 Haematological disorders Anaemia 2 Non-haematological disorders Substrates: Iron, folate, vitamin B12 Red cell mass
More informationLEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University
LEUKAEMIA and LYMPHOMA Dr Mubarak Abdelrahman Assistant Professor Jazan University OBJECTIVES Identify etiology and epidemiology for leukemia and lymphoma. Discuss common types of leukemia. Distinguish
More informationFAQs- Janet s Inbox. Janet Brunner, PA-C Wed. Feb. 26, 2014 TRAINING & DEVELOPMENT 1.
FAQs- Janet s Inbox Janet Brunner, PA-C Wed. Feb. 26, 2014 TRAINING & DEVELOPMENT 1. Disclosures I have no relevant conflicts of interest to disclose. TRAINING & DEVELOPMENT 2. Objectives 1. Determine
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL RESPONSE ASSESSMENT LYMPHOMA CHAPTER 11B REVISED: SEPTEMBER 2016
LYMPHOMA Definitions of Response According to Non Hodgkin s Lymphoma (NHL) Criteria Listed below is the new NCI Lymphoma criteria for evaluation and endpoint definitions for Non Hodgkin s Lymphoma response
More informationCase Workshop of Society for Hematopathology and European Association for Haematopathology
Case 148 2007 Workshop of Society for Hematopathology and European Association for Haematopathology Robert P Hasserjian Department of Pathology Massachusetts General Hospital Boston, MA Clinical history
More informationRecommended Timing for Transplant Consultation
REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org
More informationCASE 1. ARR 16 year old Ugandan male Senior 2 student No history of alcohol, no Tobacco
CASE 1 ARR 16 year old Ugandan male Senior 2 student No history of alcohol, no Tobacco HISTORY Index presentation to UCI, 06/09/2018 Referral Diagnosis: Burkitt s Lymphoma HISTORY 6 months of abdominal
More informationThe BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine
At the center of advances in hematology and molecular medicine Philadelphia chromosome-positive chronic myeloid leukemia Robert E. Richard MD PhD rrichard@uw.edu robert.richard@va.gov Philadelphia chromosome
More informationCHAPTER:4 LEUKEMIA. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY 8/12/2009
LEUKEMIA CHAPTER:4 1 BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Leukemia A group of malignant disorders affecting the blood and blood-forming tissues of
More informationDone By : WESSEN ADNAN BUTHAINAH AL-MASAEED
Done By : WESSEN ADNAN BUTHAINAH AL-MASAEED Acute Myeloid Leukemia Firstly we ll start with this introduction then enter the title of the lecture, so be ready and let s begin by the name of Allah : We
More informationLymphoma Case Scenario 1
Lymphoma Case Scenario 1 HISTORY: A 23-year-old healthy female presented with a month-long history of persistent headache of increasing severity. She noted episodic nausea and vomiting in association with
More informationJuvenile Myelomonocytic Leukemia (JMML)
Juvenile Myelomonocytic Leukemia (JMML) JMML: Definition Monoclonal hematopoietic disorder of childhood characterized by proliferation of the granulocytic and monocytic lineages Erythroid and megakaryocytic
More informationMultiple Myeloma 101: Understanding Your Labs
Multiple Myeloma 101: Understanding Your Labs Tim Wassenaar MD MS Hematologist, Director of Clinical Trials UW Cancer Center at ProHealth Care None Disclosures Outline Define hematopoiesis WBCs, RBCs,
More informationLeukocytosis - Some Learning Points
Leukocytosis - Some Learning Points Koh Liang Piu Department of Hematology-Oncology National University Cancer Institute National University Health System Objectives of this talk: 1. To provide some useful
More informationFBC CASES Vernon Louw Clinical Haematology 2010
FBC CASES Vernon Louw Clinical Haematology 2010 FOR EACH OF THE FOLLOWING PATIENTS, SELECT THE MOST LIKELY FINDING FROM THE ANALYSIS OF THE PERIPHERAL BLOOD. A patient with infectious mononucleosis. A
More informationPeripheral blood Pleural effusion in a cat
Tools for the Diagnosis of Lymphoproliferative Diseases When is it difficult to diagnose lymphoproliferative disease? Persistent lymphocytosis consisting of small Lymph node aspirates containing an excess
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationForm 2011 R4.0: Acute Lymphoblastic Leukemia (ALL) Pre-HCT Data
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Date of HCT for which this form is being completed: - - HCT type: (check all that apply) Autologous Allogeneic,
More informationThe patient had a mild splenomegaly but no obvious lymph node enlargement. The consensus phenotype obtained from part one of the exercise was:
Case History An 86 year old male was admitted to hospital with chest infection. Haematological examination subsequently revealed the following: Hb- 11.0 g/dl; WBC- 67.1 x 10^9/l; PLT- 99 x10^9/l; RBC-
More informationPolycthemia Vera (Rubra)
Polycthemia Vera (Rubra) Polycthemia Vera (Rubra) Increased red cells Clonal Myeloid lineages also increased 2-13 cases per million Mean age: 60 years Sites of Involvement Bone marrow Peripheral blood
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationBLASTIC CRISIS AND MYELOFIBROSIS SIMULTANEOUS COMPLICATIONS IN A CASE OF CHRONIC MYELOCYTIC LEUKEMIA
BLASTIC CRISIS AND MYELOFIBROSIS SIMULTANEOUS COMPLICATIONS IN A CASE OF CHRONIC MYELOCYTIC LEUKEMIA Abstract Pages with reference to book, From 151 To 153 Khalid Hassan ( Department of Pathology (Haematology)
More informationPathology of Hematopoietic and Lymphoid tissue
CONTENTS Pathology of Hematopoietic and Lymphoid tissue White blood cells and lymph nodes Quantitative disorder of white blood cells Reactive lymphadenopathies Infectious lymphadenitis Tumor metastasis
More informationREPORT. of Medicine, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany;
REPORT NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods
More informationADx Bone Marrow Report. Patient Information Referring Physician Specimen Information
ADx Bone Marrow Report Patient Information Referring Physician Specimen Information Patient Name: Specimen: Bone Marrow Site: Left iliac Physician: Accession #: ID#: Reported: 08/19/2014 - CHRONIC MYELOGENOUS
More informationAdult Acute leukemia. Matthew Seftel. August
Adult Acute leukemia Matthew Seftel August 21 2007 mseftel@cancercare.mb.ca Principles 3 cases Diagnosis and classification of acute leukemia (AL) Therapy Emergencies Remission induction BMT Complications
More informationLeukemia and Myelodysplastic Syndromes
Leukemia and Myelodysplastic Syndromes Lenise Taylor, RN, MN, AOCNS, BMTCN Oncology CNS Seattle Cancer Care Alliance/UWMC ltaylor@seattlecca.org Lymphoid 1 Myeloid 2 Diagnostic Evaluation of Blood Disorders
More informationAcute myeloid leukemia. M. Kaźmierczak 2016
Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production
More informationDiseases Of The Blood
Diseases Of The Blood DR. Associate Professor Of Pathology Faculty Of Medicine Ain Shams University Red Blood Cells and Anemia RBC=4-6 million/mm 2 Hb=12-18 g/dl Oxygen Carrying Molecule Hemoglobin Tetramer:
More informationHematology Unit Lab 2 Review Material
Objectives Hematology Unit Lab 2 Review Material - 2018 Laboratory Instructors: 1. Assist students during lab session Students: 1. Review the introductory material 2. Study the case histories provided
More informationAcute Lymphoblastic Leukaemia
Acute Lymphoblastic Leukaemia Terri Boyer 17 th October 2006 Overview Disease information: Aetiology of ALL proposed theory, contributing factors Symptoms Complications Diagnostic approaches - morphology
More informationEasy Trick to Spot Leukemia for Pediatricians
Easy Trick to Spot Leukemia for Pediatricians Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital Most Common Pediatric Cancers Age 0-14 Leukemia 32%
More informationWHAT ARE PAEDIATRIC CANCERS
WHAT ARE PAEDIATRIC CANCERS INTRODUCTION Childhood cancers are RARE 0.5% of all cancers in the West Overall risk that a child will develop cancer during first 15 years of life is 1 in 450 and 1 in 600
More informationBlood Cancers in the Community
Over to you, mate Blood Cancers in the Community National Rural Health Conference NZ Rural General Practice Network April 7, 2018 Brian Grainger Haematology Registrar Auckland Acknowledgements Dr James
More informationThe Lymphomas. An overview..
The Lymphomas An overview.. Peter Anglin MD, FRCPC, MBA Stronach Regional Cancer Centre Newmarket, ON The lymphomas are an important part of the history of medicine 1666 Magpighi publishes first recorded
More informationExtramedullary precursor T-lymphoblastic transformation of CML at presentation
Extramedullary precursor T-lymphoblastic transformation of CML at presentation Neerja Vajpayee, Constance Stein, Bernard Poeisz & Robert E. Hutchison Clinical History 30 year old man presented to the emergency
More informationMECHANISMS OF HUMAN DISEASE: LABORATORY SESSIONS LYMPHOMA. April 16, 2008
MECHANISMS OF HUMAN DISEASE: LABORATORY SESSIONS LYMPHOMA April 16, 2008 FACULTY COPY GOAL: Learn the appearance of normal peripheral blood elements and lymph nodes. Recognize abnormal peripheral blood
More informationWBCs Disorders. Dr. Nabila Hamdi MD, PhD
WBCs Disorders Dr. Nabila Hamdi MD, PhD ILOs Compare and contrast ALL, AML, CLL, CML in terms of age distribution, cytogenetics, morphology, immunophenotyping, laboratory diagnosis clinical features and
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationPathology of Hematopoietic and Lymphoid tissue
Pathology of Hematopoietic and Lymphoid tissue Peerayut Sitthichaiyakul, M.D. Department of Pathology and Forensic Medicine Faculty of Medicine, Naresuan University CONTENTS White blood cells and lymph
More informationMyeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas. James J. Stark, MD, FACP
Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS
More informationCommon Haematological Problems in Primary Care
23 rd March 2019 GP Hot Topics In Primary Care Common Haematological Problems in Primary Care Dr Samar Kulkarni Consultant Haematologist-Oncologist and The Christie Private Care Manchester, UK. Haematology?
More informationCHALLENGING CASES PRESENTATION
CHALLENGING CASES PRESENTATION Michael C. Wiemann, MD, FACP Program Co-Chair and Vice President Indy Hematology Education President, Clinical St. John Providence Physician Network Detroit, Michigan 36
More informationTable 1: biological tests in SMD
Table 1: biological tests in SMD Tests Mandatory Recommended Under validation Morphology Marrow aspirate Marrow biopsy 1 Iron staining Quantification of dysplasia WHO 2008 Classification Cytogenetics Conventional
More informationMyelodysplastic syndrome (MDS) & Myeloproliferative neoplasms
Myelodysplastic syndrome (MDS) & Myeloproliferative neoplasms Myelodysplastic syndrome (MDS) A multipotent stem cell that can differentiate into any of the myeloid lineage cells (RBCs, granulocytes, megakaryocytes)
More informationAnaemias and other Pesky Haematology Questions
Anaemias and other Pesky Haematology Questions 3 main topics How do I work out an anaemia.. That oh too common paraprotein patient. Those mildly raised lymphocyte count GP discussed patient with me over
More informationHow To Do A Manual White Blood Cell Count Up After Chemotherapy
How To Do A Manual White Blood Cell Count Up After Chemotherapy Typically, the greatest impact is on white blood cells. Before, during, and after chemotherapy, do your best to follow the common-sense Before
More informationBlood Cancer: Chronic Myelogenous Leukaemia
Published on: 30 May 2017 Blood Cancer: Chronic Myelogenous Leukaemia What Is Cancer? The body is made up of cells that grow and die in a controlled way. Sometimes, cells keep dividing and growing without
More informationIntegrated Diagnostic Approach to the Classification of Myeloid Neoplasms. Daniel A. Arber, MD Stanford University
Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms Daniel A. Arber, MD Stanford University What is an integrated approach? What is an integrated approach? Incorporating all diagnostic
More informationClinical & Laboratory Assessment
Clinical & Laboratory Assessment Dr Roger Pool NHLS & University of Pretoria Clinical Assessment (History) Anaemia ( haemoglobin) Dyspnoea (shortness of breath) Tiredness Angina Headache Clinical Assessment
More informationSmoldering Multiple Myeloma. A Case Study
Smoldering Multiple Myeloma A Case Study Case Presentation 53-Year-Old Male Patient presented for a routine exam No prior history of disease or family history of fhematologic disorders d or malignancies,
More informationFuture Direction for Cancer Registries
Future Direction for Cancer Registries Sally Vernon Head of Quality and Analysis Eastern Cancer Registry and Information Centre sally.vernon@ecric.nhs.uk In Ye Olde Days. 8 regional cancer registries Variation
More informationEvaluation of Bone Marrow Biopsies and Aspirates ANNA PORWIT DEPARTMENT OF PATHOLOGY, LUND UNIVERSITY
Evaluation of Bone Marrow Biopsies and Aspirates ANNA PORWIT DEPARTMENT OF PATHOLOGY, LUND UNIVERSITY DISCLOSURES NONE Learning objectives To review the rules of BMA evaluation To review the main issues
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care
More informationAll Wales Lymphoma Panel Lymphoma Course April 2015 Wales Millennium Centre Cardiff
All Wales Lymphoma Panel Lymphoma Course 23-24 April 2015 Wales Millennium Centre Cardiff Case Histories Online slides at: http://dental.uwcm.ac.uk:82/awlp%20course%202015/view.apml? Professor Sebastian
More informationCandidates must answer ALL questions
Time allowed: Three hours. Part 1 examination Haematology: First paper Tuesday 22 March 2016 Candidates must answer ALL questions Question 1: General Haematology A 16 year old non-european is referred
More informationClassification of Hematologic Malignancies. Patricia Aoun MD MPH
Classification of Hematologic Malignancies Patricia Aoun MD MPH Objectives Know the basic principles of the current classification system for hematopoietic and lymphoid malignancies Understand the differences
More informationFBC interpretation. Dr. Gergely Varga
FBC interpretation Dr. Gergely Varga #1 71 Y/O female, c/o weakness Test Undertaken : FBC (FBC) Sample Type: Whole Blood [ - 26.09.11 14:59] Hb 7.3 g/dl* 12.0-15.5 RBC 3.5 10^12/l * 3.80-5.60 Hct 0.24
More information2013 Pathology Student
About this guide If you re reading this introduction, it means you are probably either a) covering hematopathology in your pathology class right now, or b) studying for boards. Either way, you ve come
More informationTRANSPARENCY COMMITTE OPINION. 19 December 2007
The legally binding text is the original French version TRANSPARENCY COMMITTE OPINION 19 December 2007 ATRIANCE 5 mg/ml, Solution for Infusion Pack of 6 vials (571 348-9) Applicant: GlaxoSmithKline nelarabine
More informationWelcome to Master Class for Oncologists. Session 3: 9:15 AM - 10:00 AM
Welcome to Master Class for Oncologists Session 3: 9:15 AM - 10:00 AM Miami, FL December 18, 2009 Myeloproliferative Neoplasms: Bringing Order to Complexity and Achieving Optimal Outcomes Speaker: Andrew
More informationAcute Lymphoblastic and Myeloid Leukemia
Acute Lymphoblastic and Myeloid Leukemia Pre- and Post-Disease Form Acute Lympoblastic Leukemia Mary Eapen MD, MS Acute Lymphoblastic Leukemia SEER Age-adjusted incidence rate 1.6 per 100,000 men and women
More informationModule 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning
Module 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning Challenge Question: Role of Autologous Stem Cell Transplant Which of the following is true about eligibility for high-dose
More informationChronic Myelogenous Leukemia in a 66-Year-Old Male with Concurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Myelogenous Leukemia in a 66-Year-Old Male with Concurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Linda J. Szymanski, DO, 1 Hashem Ayyad, MD, 1 Kedar Inamdar, MD, PhD 1* CLINICAL
More information